IP Library › Granted Patent US 12,318,382
Granted Patent B2
US 12,318,382 · App. 17/282,584 · Granted Jun 3, 2025

Methods of treating rheumatic diseases using trimetazidine-based compounds

Inventors: Andrew D. Levin (Newton, MA); David-Alexandre Gros (Rancho Santa Fe, CA); Jaikrishna Patel (Cary, NC)
Assignee: IMBRIA PHARMACEUTICALS, INC.
A61K31/496A61K9/0019A61K9/0053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,382
App. No.
17/282,584
Granted
Jun 3, 2025
Kind
B2
Abstract

The invention provides compositions and methods for treating a subject having a rheumatic condition.

Claims (13)

1. A method of treating a rheumatic disease, disorder, or condition in a subject, the method comprising providing to a subject having a rheumatic disease, disorder, or condition a composition comprising a compound represented by formula (X):

wherein the rheumatic disease, disorder, or condition is selected from the group consisting of ankylosing spondylitis, autoimmune-related lung disease, Behcet's Disease, bursitis, cachexia, cardiac fibrosis, claudication, dermatomyositis, frailty, gout, inflammatory arthritis, inflammatory eye disease, inflammatory myositis, juvenile idiopathic arthritis, muscle myopathy, myofascial pain syndrome, myositis, osteoarthritis, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, pulmonary arterial hypertension, pulmonary fibrosis, rheumatoid arthritis, sarcopenia, scleroderma, Sjögren's syndrome, tendinitis, tinnitus, vasculitis, and vertigo.

2. The method of claim 1 , wherein the composition is administered in a single unit dose.

3. The method of claim 1 , wherein the composition is administered in a dose comprising multiple units.

4. The method of claim 1 , wherein the composition is formulated for oral administration.

5. The method of claim 1 , wherein the composition is formulated for intravenous administration.

6. A method of treating a rheumatic disease, disorder, or condition in a subject, the method comprising providing to a subject having a rheumatic disease, disorder, or condition a composition comprising a compound represented by formula (IX):

wherein the rheumatic disease, disorder, or condition is selected from the group consisting of ankylosing spondylitis, autoimmune-related lung disease, Behcet's Disease, bursitis, cachexia, cardiac fibrosis, claudication, dermatomyositis, frailty, gout, inflammatory arthritis, inflammatory eye disease, inflammatory myositis, juvenile idiopathic arthritis, muscle myopathy, myofascial pain syndrome, myositis, osteoarthritis, osteoporosis, polymyalgia rheumatica, polymyositis, psoriatic arthritis, pulmonary arterial hypertension, pulmonary fibrosis, rheumatoid arthritis, sarcopenia, scleroderma, Sjögren's syndrome, tendinitis, tinnitus, vasculitis, and vertigo.

7. The method of claim 6 , wherein the composition is administered in a single unit dose.

8. The method of claim 6 , wherein the composition is administered in a dose comprising multiple units.

9. The method of claim 6 , wherein the composition is formulated for oral administration.

10. The method of claim 6 , wherein the composition is formulated for intravenous administration.

11. The method of claim 1 , wherein the rheumatic disease, disorder or condition is rheumatoid arthritis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2021
From: LEVIN, ANDREW D.; GROS, DAVID-ALEXANDRE; PATEL, JAI
To: IMBRIA PHARMACEUTICALS, INC.
Reel/Frame 055817/0776 →
Continuity (4)
Provisional Application 62819819 · Mar 18, 2019
Provisional Application 62757805 · Nov 9, 2018
Provisional Application 62746670 · Oct 17, 2018
Related Publication 20210353617A1 · Nov 18, 2021
References Cited (163)
US 4100285A · Murai · 1978 [cited by examiner]
US 4166452A · Generales, Jr. · 1979 [cited by applicant]
US 4256108A · Theeuwes · 1981 [cited by applicant]
US 4265874A · Bonsen et al. · 1981 [cited by applicant]
US 4574156A · Morita et al. · 1986 [cited by applicant]
US 4845099A · Ruger et al. · 1989 [cited by applicant]
US 4876257A · Hajos et al. · 1989 [cited by applicant]
US 4885300A · Press et al. · 1989 [cited by applicant]
US 5077288A · Lavielle et al. · 1991 [cited by applicant]
US 5286728A · Ferrini · 1994 [cited by applicant]
US 5340809A · Gaudry et al. · 1994 [cited by applicant]
US 5380726A · Ferrini · 1995 [cited by applicant]
US 5384319A · Ferrini · 1995 [cited by applicant]
US 5397780A · Mizuno et al. · 1995 [cited by applicant]
US 5399557A · Mizuno et al. · 1995 [cited by applicant]
US 5401743A · Rendenbach-Mueller et al. · 1995 [cited by applicant]
US 5428038A · Chatterjee et al. · 1995 [cited by applicant]
US 5527800A · Goto et al. · 1996 [cited by applicant]
US 5591849A · Kato et al. · 1997 [cited by applicant]
US 5641779A · Halazy et al. · 1997 [cited by applicant]
US 5770735A · Emonds-Alt et al. · 1998 [cited by applicant]
US 5776937A · Gante et al. · 1998 [cited by applicant]
US 5849745A · Wierzbicki et al. · 1998 [cited by applicant]
US 5856326A · Anthony et al. · 1999 [cited by applicant]
US 5962448A · Mizuno et al. · 1999 [cited by applicant]
US 5977111A · Mizuno et al. · 1999 [cited by applicant]
US 6087346A · Glennon et al. · 2000 [cited by applicant]
US 6121267A · Glase et al. · 2000 [cited by applicant]
US 6200989B1 · De Cillis et al. · 2001 [cited by applicant]
US 6214841B1 · Jackson et al. · 2001 [cited by applicant]
US 6271223B1 · Mizuno et al. · 2001 [cited by applicant]
US 6331623B1 · Mizuno et al. · 2001 [cited by applicant]
US 6528529B1 · Brann et al. · 2003 [cited by applicant]
US 6562978B1 · Imamura et al. · 2003 [cited by applicant]
US 6693099B2 · Degenhardt et al. · 2004 [cited by applicant]
US 7638531B2 · Mutahi et al. · 2009 [cited by applicant]
US 7666866B2 · Franciskovich et al. · 2010 [cited by applicant]
US 7772251B2 · Sturzebecher et al. · 2010 [cited by applicant]
US 7968538B2 · Becker et al. · 2011 [cited by applicant]
US 8016783B2 · Pastore et al. · 2011 [cited by applicant]
US 8202901B2 · Lopaschuk et al. · 2012 [cited by applicant]
US 8461117B2 · Sufi et al. · 2013 [cited by applicant]
US 8569495B2 · Chassaing et al. · 2013 [cited by applicant]
US 8697661B2 · Kritikou · 2014 [cited by applicant]
US 9096538B2 · Nakamura et al. · 2015 [cited by applicant]
US 9120801B2 · Alisi et al. · 2015 [cited by applicant]
US 10167258B2 · Chuang et al. · 2019 [cited by applicant]
US 10556013B2 · Levin · 2020 [cited by applicant]
US 10918728B2 · Levin · 2021 [cited by applicant]
US 10953102B2 · Levin · 2021 [cited by examiner]
US 11730733B2 · Patel · 2023 [cited by examiner]
US 11793807B2 · Patel · 2023 [cited by examiner]
US 11844840B2 · Levin · 2023 [cited by examiner]
US 11883396B2 · Chamberlin · 2024 [cited by examiner]
US 20020137798A1 · Mueller · 2002 [cited by examiner]
US 20030191182A1 · Lopaschuk et al. · 2003 [cited by applicant]
US 20030232877A1 · Sikorski et al. · 2003 [cited by applicant]
US 20040082564A1 · Arrhenius et al. · 2004 [cited by applicant]
US 20050004121A1 · Palani et al. · 2005 [cited by applicant]
US 20070004750A1 · Lorsbach et al. · 2007 [cited by applicant]
US 20080108618A1 · Brann et al. · 2008 [cited by applicant]
US 20080161400A1 · Virsik et al. · 2008 [cited by applicant]
US 20090197891A1 · Lecanu et al. · 2009 [cited by applicant]
US 20090258064A1 · Newell et al. · 2009 [cited by applicant]
US 20100022530A1 · Schiemann et al. · 2010 [cited by applicant]
US 20110046370A1 · Sim et al. · 2011 [cited by applicant]
US 20110137362A1 · Foreman et al. · 2011 [cited by applicant]
US 20110212072A1 · Henkel et al. · 2011 [cited by applicant]
US 20120214818A1 · Dudley · 2012 [cited by applicant]
US 20160060530A1 · Archetti et al. · 2016 [cited by applicant]
US 20160346397A1 · Milne et al. · 2016 [cited by applicant]
US 20170008950A1 · Capon · 2017 [cited by applicant]
US 20170105414A1 · Nakano et al. · 2017 [cited by applicant]
US 20180360975A1 · Levin · 2018 [cited by examiner]
US 20190084917A1 · Savourey et al. · 2019 [cited by applicant]
US 20190216936A1 · Levin · 2019 [cited by applicant]
US 20200138963A1 · Levin · 2020 [cited by applicant]
US 20210353617A1 · Levin et al. · 2021 [cited by applicant]
CA 2170615A1 · 1995 [cited by applicant]
CA 2186010A1 · 1995 [cited by applicant]
CN 101747292B · 2011 [cited by applicant]
DE 2714996A1 · 1977 [cited by applicant]
EP 0144991A2 · 1985 [cited by applicant]
EP 0251141A1 · 1988 [cited by applicant]
EP 615855A1 · 1994 [cited by applicant]
EP 661266A1 · 1995 [cited by applicant]
EP 749967A1 · 1996 [cited by applicant]
EP 1634598A1 · 2006 [cited by applicant]
EP 1886994A1 · 2008 [cited by applicant]
EP 2727916A1 · 2014 [cited by applicant]
JP S57131777 · 1982 [cited by applicant]
JP 2000147773A · 2000 [cited by applicant]
JP 2006113343A · 2006 [cited by applicant]
JP 2015017236A · 2015 [cited by applicant]
WO 1995000165A1 · 1995 [cited by applicant]
WO 9626196A2 · 1996 [cited by applicant]
WO 9630054A1 · 1996 [cited by applicant]
WO 9630343A1 · 1996 [cited by applicant]
WO 9728141A1 · 1997 [cited by applicant]
WO 9746549A1 · 1997 [cited by applicant]
WO 9858638A1 · 1998 [cited by applicant]
WO 9950247A1 · 1999 [cited by applicant]
WO 2001005763A2 · 2001 [cited by applicant]
WO 2002058698A2 · 2002 [cited by applicant]
WO 2002064576A1 · 2002 [cited by applicant]
WO 2003006628A2 · 2003 [cited by applicant]
WO 2006027223A1 · 2006 [cited by applicant]
WO 2006117686A2 · 2006 [cited by applicant]
WO 2006133784A1 · 2006 [cited by applicant]
WO 2007075629A2 · 2007 [cited by applicant]
WO 2007096251A1 · 2007 [cited by applicant]
WO 2007116074A1 · 2007 [cited by applicant]
WO 2007116243A2 · 2007 [cited by applicant]
WO 2008109991A1 · 2008 [cited by applicant]
WO 2009015485A1 · 2009 [cited by applicant]
WO 2009058818A2 · 2009 [cited by applicant]
WO 2009066315A2 · 2009 [cited by applicant]
WO 2009156479A1 · 2009 [cited by applicant]
WO 2011032099A1 · 2011 [cited by applicant]
WO 2012049101A1 · 2012 [cited by applicant]
WO 2015018660A1 · 2015 [cited by applicant]
WO 2016005576A1 · 2016 [cited by applicant]
WO 2016107603A1 · 2016 [cited by applicant]
WO 2018236745A1 · 2018 [cited by applicant]
WO 2020081361A1 · 2020 [cited by applicant]
Levy (Curr. Emerg. Hosp Med. Rep. vol. 2 pp. 126-132 published 2014) (Year: 2014). [cited by examiner]
Bhosle, 2006, Mutual Prodrug Concept: Fundamentals and Applications, Indian Journal of Pharmaceutical Sciences, May-June, pp. 286-294. [cited by applicant]
Cheng, 2006, Discovery of Potent and Orally Available Malonyl-CoA Decarboxylase Inhibitors as Cardioprotective Agents, J. Med. Chem. 49:4055-4058. [cited by applicant]
Cheng, 2006, Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors, J. Med. Chem. 49:1517-1525. [cited by applicant]
Das, 1995, Essential Fatty Acid Metabolism in Patients with Essential Hypertension, Diabetes Mellitus and Coronary Heart Disease, Prostaglandins Leukotrienes and Essential Fatty Acids, 52, 387-391. [cited by applicant]
Extended European Search Report issued in European Application No. 18821590.9, date of mailing: Oct. 5, 2020, 33 pages. [cited by applicant]
Fang et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle, Journal of Molecular Medicine, Aug. 28, 2011, vol. 90, pp. 31-43. [cited by applicant]
Fang et al., Therapeutic Inhibition of fatty acid oxidation in right ventricular hypertrophy; exploiting Randle's cycle, Journal of Molecular Medicine, Aug. 28, 2011, vol. 90, p. 31-43, abstract, p. 4, left col. para 1,… [cited by applicant]
Fillmore, 2014, Malonyl CoA: A Promising Target for the Treatment of Cardiac Disease, Int. Union of Biochem. and Mol. Biol., 66(3):139-146. [cited by applicant]
Fillmore, 2014, Mitochondrial fatty acid oxidation alterations in heart failure, ischemic heart disease and diabetic cardiomyopathy, Brit. J. Pharmacol. 171:2080-2090. [cited by applicant]
Folmes, 2005, Fatty Acid Oxidation Inhibitors in the Management of Chronic Complications of Atherosclerosis, Current Atherosclerosis Reports 2005, 7, 63-70. [cited by applicant]
Gibbs, 1995, Cardiac efficiency, Cardiovasc. Res. 30:627-634. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/034611, date of mailing: Oct. 14, 2020, 45 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/34608, date of mailing: Oct. 14, 2020, 28 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2020/34609, date of mailing: Oct. 14, 2020, 22 pages. [cited by applicant]
International Search Report and Written Opinion mailed Nov. 5, 2018, for International Patent Application PCT/US2018/038067 with International filing date Jun. 18, 2018 (11 pages). [cited by applicant]
Kantor, 2000, The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase, Circulation Researc… [cited by applicant]
Leriche, 2012, Cleavable linkers in chemical biology, Bioorg. Med. Chem. 20:571-582. [cited by applicant]
Levy, 2014, Vasodilators in Acute Heart Failure: Review of the Latest Studies, Curr Emerg Hosp Med Rep, 2 (2):126-134. [cited by applicant]
Lopaschuk, 2010, Myocardial Fatty Acid Metabolism in Health and Disease, Phys. Rev. 90:207-258. [cited by applicant]
Morin, 1998, Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore, Brit. J. Pharmacol. 123:1385-1394. [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 16/722,691, date of mailing: Aug. 19, 2020, 12 pages. [cited by applicant]
Pubchem, CID 2223657, Jul. 15, 2005, pp. 1-14. [cited by applicant]
Reddy, 2006, Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation, Am J Physiol Gastrointest Liver Physiol, 290: G852-G858. [cited by applicant]
Sabbah, 2005, Metabolic Therapy for Heart Disease: Impact of Trimetazidine, Heart Failure Reviews, 10, 281-288. [cited by applicant]
Schipke, 1994, Cardiac efficiency, Basic Res. Cardiol. 89:207-40. [cited by applicant]
Spiekerkoetter, 2010, Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening, J Inherit Metab Dis, 33:527-532. [cited by applicant]
Steggall et al., Targeting Metabolic Modulation and Mitochondiral Dysfunction in the Treatment of Heart Failure Diseases, May 10, 2017, vol. 5, pp. 1-18. [cited by applicant]
The Merck Manual List of Diseases https://merckmanuals.com/professional (accessed Jan. 17, 2020), 4 pages. [cited by applicant]
Trammell, 2016, Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, Nat. Commun. 7:12948, 14 pages. [cited by applicant]
Visser, 2008, Measuring cardiac efficiency: is it clinically useful? Heart Metab. 39:3-4. [cited by applicant]
Extended European Search Report issued in European Application No. 19872680.4, date of mailing: Jun. 20, 2022, 7 pages. [cited by applicant]
Gallaher, 1993, Viscosity and Fermentability as Attributes of Dietary Fiber Responsible of rhte Hypocholesterolemnic Effect in Hamsters, J Nutr., 123, pp. 244-252. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2021/039303, date of mailing: Nov. 26, 2021, 19 pages. [cited by applicant]
International Search Report issued in an International Application No. PCT/US2021/030450, date of mailing: Sep. 27, 2021, 9 pages. [cited by applicant]
Kotreka, 2011, Gastroretentive Floating Drug-Delivery Systems: A Critical Review, Critical Reviews in Therapeutic Drug Carrier Systems, 28(1):47-99. [cited by applicant]
Sannino, 2009, Biodegradable Cellulose-based Hydrogels: Design and Applications, Materials, 2:353-373. [cited by applicant]
Steggall, 2017, Targeting metabolic modulation and mitochondiral dysfunction in the treatment of heart failure, Diseases, 5(14):1-18. [cited by applicant]
Cited By (2)
US 12,569,480 US 12,649,720